Literature DB >> 21123093

Clinical pathways improve hospital resource use in endocrine surgery.

Rajan P Kulkarni1, Philip H-G Ituarte, Douglas Gunderson, Michael W Yeh.   

Abstract

BACKGROUND: Clinical pathways are increasingly adopted to streamline care after elective surgery. Here, we describe novel clinical pathways developed for endocrine operations (ie, unilateral thyroid lobectomy, total thyroidectomy, parathyroidectomy) and evaluate their effects on economic end points at a major academic hospital. STUDY
DESIGN: Length of stay (LOS), hospital charges, and hospital costs for 681 patients undergoing elective endocrine surgery during a 30-month period were compared between patients managed with or without a specific pathway. Hospital costs were subcategorized by cost center. The analysis arms were conducted concurrently to control for institutional effects and end points were adjusted for demographic factors and comorbidity.
RESULTS: Clinical pathways were observed to significantly reduce LOS, charges, and costs for endocrine procedures. LOS was reduced for thyroid lobectomy (nonpathway 1.6 days versus pathway 1.0; p < 0.001), total thyroidectomy (2.8 versus 1.1; p < 0.0001), and parathyroidectomy (1.6 versus 1.1; p < 0.001). Nonpathway patients were 6.2 times more likely to be admitted to the intensive care unit than pathway patients (p < 0.05). Clinical pathways reduced total charges from $21,941 to $17,313 for all cases (21% reduction; p < 0.0001), with 47% of savings attributable to reduced LOS. Significant improvements were observed for laboratory use (73% reduction; p < 0.0001) and nonroutine medication administration (73% reduction; p < 0.0001). The readmission rate within 72 hours of discharge was not significantly lower in the pathway group.
CONCLUSIONS: Implementation of clinical pathways improves efficiency of care after elective endocrine surgery without adversely affecting safety or quality. Because these system measures optimize resource use, they represent an important component of high-volume subspecialty surgical services.
Copyright © 2011 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21123093     DOI: 10.1016/j.jamcollsurg.2010.09.016

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  6 in total

1.  Compliance of Clinical Pathways in Elective Laparoscopic Cholecystectomy: Evaluation of Different Implementation Methods.

Authors:  Martin Holderried; Rebecca Hummel; Claudius Falch; Andreas Kirschniak; Alfred Koenigsrainer; Christian Ernst; Sven Muller
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

2.  Comparison of minimally invasive parathyroidectomy under local anaesthesia and minimally invasive video-assisted parathyroidectomy for primary hyperparathyroidism: a cost analysis.

Authors:  G I Melfa; C Raspanti; M Attard; G Cocorullo; A Attard; S Mazzola; G Salamone; G Gulotta; G Scerrino
Journal:  G Chir       Date:  2016 Mar-Apr

3.  An intact parathyroid hormone-based protocol for the prevention and treatment of symptomatic hypocalcemia after thyroidectomy.

Authors:  Yvette Carter; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2013-10-08       Impact factor: 2.192

4.  Strategic impact of a new academic endocrine surgery program.

Authors:  James E Wiseman; Philip H G Ituarte; Roy S Hwang; Ilan Safir; Jesse D Pasternak; Karen Van Nuys; Michael W Yeh
Journal:  Ann Surg Oncol       Date:  2011-02-23       Impact factor: 5.344

5.  Endocrine surgery as a model for value-based health care delivery.

Authors:  Amer G Abdulla; Philip H G Ituarte; Randi Wiggins; Elizabeth O Teisberg; Avital Harari; Michael W Yeh
Journal:  Surg Neurol Int       Date:  2012-12-26

6.  Outcomes of Critical Pathway in Laparoscopic and Open Surgical Treatments for Gastric Cancer Patients: Patients Selection for Fast-Track Program through Retrospective Analysis.

Authors:  Ji Woo Choi; Yi Xuan; Hoon Hur; Cheul Su Byun; Sang-Uk Han; Yong Kwan Cho
Journal:  J Gastric Cancer       Date:  2013-06-25       Impact factor: 3.720

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.